INSULIN RESISTANCE

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In men with prostate cancer, treatment with a GnRH agonist is associated with increased risk of diabetes mellitus and cardiovascular disease. Short-term GnRH agonist treatment decreases insulin sensitivity, suggesting that treatment-related insulin resistance may contribute to risk of diabetes and cardiovascular disease in men with prostate cancer. Two main questions arise from the latter observation. First, what are the effects of longer-term treatment on insulin sensitivity? Second, are the changes in insulin sensitivity reversible after discontinuation of treatment? This study will attempt to address both questions.